AR069520A1 - Utilizacion de una cepa de l. casei para la preparacion de una composicion para inhibir la activacion de mastocitos - Google Patents
Utilizacion de una cepa de l. casei para la preparacion de una composicion para inhibir la activacion de mastocitosInfo
- Publication number
- AR069520A1 AR069520A1 ARP080105236A ARP080105236A AR069520A1 AR 069520 A1 AR069520 A1 AR 069520A1 AR P080105236 A ARP080105236 A AR P080105236A AR P080105236 A ARP080105236 A AR P080105236A AR 069520 A1 AR069520 A1 AR 069520A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- strain
- use indicated
- indicated
- preparation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 10
- 244000199866 Lactobacillus casei Species 0.000 title abstract 3
- 230000004913 activation Effects 0.000 title 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 6
- 230000001580 bacterial effect Effects 0.000 abstract 5
- 230000020411 cell activation Effects 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 abstract 2
- 241000186000 Bifidobacterium Species 0.000 abstract 1
- 241000186660 Lactobacillus Species 0.000 abstract 1
- 240000001929 Lactobacillus brevis Species 0.000 abstract 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 abstract 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 abstract 1
- 241000194036 Lactococcus Species 0.000 abstract 1
- 241000194017 Streptococcus Species 0.000 abstract 1
- 241000194020 Streptococcus thermophilus Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003710 calcium ionophore Substances 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 abstract 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 abstract 1
- 229940039696 lactobacillus Drugs 0.000 abstract 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 abstract 1
- 239000006166 lysate Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291431A EP2065048A1 (en) | 2007-11-30 | 2007-11-30 | Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069520A1 true AR069520A1 (es) | 2010-01-27 |
Family
ID=39323735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105236A AR069520A1 (es) | 2007-11-30 | 2008-12-01 | Utilizacion de una cepa de l. casei para la preparacion de una composicion para inhibir la activacion de mastocitos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100284973A1 (https=) |
| EP (2) | EP2065048A1 (https=) |
| JP (1) | JP2011505349A (https=) |
| CN (1) | CN101909643A (https=) |
| AR (1) | AR069520A1 (https=) |
| RU (1) | RU2010126596A (https=) |
| WO (1) | WO2009068997A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2924307B1 (fr) * | 2007-12-04 | 2010-08-27 | Gervais Danone Sa | Utilisation de l. casei ssp. paracasei comme antifongique |
| WO2010013143A2 (en) * | 2008-08-01 | 2010-02-04 | Institut Pasteur | Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus |
| CN103097513B (zh) * | 2010-03-12 | 2018-01-30 | 热尔韦·达诺尼公司 | 用于乳糜泻的乳酸菌 |
| KR101275227B1 (ko) * | 2010-10-13 | 2013-06-18 | 광주과학기술원 | 중증근무력증 예방, 개선 또는 치료용 조성물 |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CN103257237B (zh) * | 2013-05-09 | 2015-05-20 | 中国农业大学 | 一种食品中过敏原的体外检测方法 |
| EP3400953A1 (en) | 2014-12-23 | 2018-11-14 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| AR103260A1 (es) | 2014-12-23 | 2017-04-26 | 4D Pharma Res Ltd | Modulación inmunitaria |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SMT201900588T1 (it) | 2015-06-15 | 2019-11-13 | 4D Pharma Res Limited | Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| CN108513545B (zh) | 2015-11-20 | 2020-11-03 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EP3387156B1 (en) * | 2015-12-11 | 2020-04-29 | PrecisionBiotics Group Limited | Lactobacillus casei for treating obesity and associated metabolic disorders |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| ME03487B (me) | 2016-03-04 | 2020-01-20 | 4D Pharma Plc | Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| DK3630136T3 (da) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| SMT202000555T1 (it) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi |
| CA3066189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| SMT202000695T1 (it) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Limited | Composizioni comprendenti ceppi batterici |
| SG11202005863TA (en) * | 2018-01-12 | 2020-07-29 | Gi Innovation Inc | Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof |
| CN109266584B (zh) * | 2018-10-18 | 2020-09-08 | 扬州大学 | 一株具有肥大细胞活性调节作用的纤毛型鼠李糖乳杆菌及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2617758B2 (ja) * | 1988-03-25 | 1997-06-04 | 株式会社ヤクルト本社 | 抗体産生増強型免疫賦活剤 |
| CN1099271A (zh) * | 1993-08-23 | 1995-03-01 | 王世荣 | 生态口服液 |
| CN1114354A (zh) * | 1994-06-23 | 1996-01-03 | 江苏省纺织(集团)总公司实业开发分公司 | 双歧杆菌在含中药培养基中进行有氧发酵的方法 |
| AUPQ415899A0 (en) * | 1999-11-19 | 1999-12-16 | Vasse Research Institute Pty Ltd | Compositions for and methods of treatment of allergic diseases |
| JP4580542B2 (ja) * | 2000-05-17 | 2010-11-17 | 株式會社バイオニア | 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物 |
| PE20030283A1 (es) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| US20030092163A1 (en) * | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| CN1289092C (zh) * | 2002-10-29 | 2006-12-13 | 西安大鹏生物科技股份有限公司 | 一种肠道微生态调节剂 |
| FR2848115B1 (fr) * | 2002-12-05 | 2005-03-25 | Rhodia Chimie Sa | Composition de bacteries et son utilisation |
| PL1675481T3 (pl) * | 2003-10-24 | 2009-03-31 | Nutricia Nv | Kompozycja synbiotyczna dla niemowląt |
| CN100396771C (zh) * | 2004-05-10 | 2008-06-25 | 景岳生物科技股份有限公司 | 新的微生物株类干酪乳杆菌gm-080及其治疗过敏相关疾病的用途 |
| US7351572B2 (en) * | 2004-10-15 | 2008-04-01 | Genmont Biotech Inc. | Microorganism strain GM-090 of Lactobacillus fermentum and its use for stimulating IFN-γ secretion and/or treating allergy |
| EP1683425A1 (en) * | 2005-01-21 | 2006-07-26 | Compagnie Gervais Danone | Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction |
| EP1945234B1 (en) * | 2005-09-23 | 2012-12-19 | Gwangju Institute of Science and Technology | Composition for preventing or treating arthritis comprising lactic acid bacteria and collangen as active ingredients |
| CN100556414C (zh) * | 2005-10-14 | 2009-11-04 | 德阳创新生物工程有限公司 | 一种具免疫调节功能的多菌组合物及其制备方法与用途 |
| JP2007117031A (ja) * | 2005-10-31 | 2007-05-17 | Nakagaki Gijutsushi Jimusho:Kk | インターフェロンガンマ発現誘導作用を有する発酵乳、及び発酵乳製造用種菌 |
-
2007
- 2007-11-30 EP EP07291431A patent/EP2065048A1/en not_active Withdrawn
-
2008
- 2008-12-01 CN CN200880124467XA patent/CN101909643A/zh active Pending
- 2008-12-01 RU RU2010126596/15A patent/RU2010126596A/ru unknown
- 2008-12-01 JP JP2010535473A patent/JP2011505349A/ja active Pending
- 2008-12-01 US US12/745,079 patent/US20100284973A1/en not_active Abandoned
- 2008-12-01 EP EP08854776A patent/EP2224936A1/en not_active Withdrawn
- 2008-12-01 WO PCT/IB2008/003690 patent/WO2009068997A1/en not_active Ceased
- 2008-12-01 AR ARP080105236A patent/AR069520A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011505349A (ja) | 2011-02-24 |
| WO2009068997A1 (en) | 2009-06-04 |
| EP2224936A1 (en) | 2010-09-08 |
| US20100284973A1 (en) | 2010-11-11 |
| CN101909643A (zh) | 2010-12-08 |
| RU2010126596A (ru) | 2012-01-10 |
| EP2065048A1 (en) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069520A1 (es) | Utilizacion de una cepa de l. casei para la preparacion de una composicion para inhibir la activacion de mastocitos | |
| Atassi et al. | Diverse expression of antimicrobial activities against bacterial vaginosis and urinary tract infection pathogens by cervicovaginal microbiota strains of Lactobacillus gasseri and Lactobacillus crispatus | |
| Lin et al. | Effect of probiotic lactobacilli on the growth of Streptococcus mutans and multispecies biofilms isolated from children with active caries | |
| JP2011505349A5 (https=) | ||
| Mashima et al. | Interaction between Streptococcus spp. and Veillonella tobetsuensis in the early stages of oral biofilm formation | |
| Belizário et al. | Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches | |
| Jeong et al. | Antimicrobial and anti-biofilm activities of Lactobacillus kefiranofaciens DD2 against oral pathogens | |
| Al‐Ghazzewi et al. | Effect of konjac glucomannan hydrolysates and probiotics on the growth of the skin bacterium Propionibacterium acnes in vitro | |
| Woo et al. | Probiotic‐mediated competition, exclusion and displacement in biofilm formation by food‐borne pathogens | |
| Shen et al. | Engineering the gut microbiota to treat hyperammonemia | |
| RU2009133376A (ru) | Способы и наборы для введения пробиотиков | |
| ES2524432T3 (es) | Bacterias del ácido láctico como cepas probióticas y composiciones que contienen las mismas | |
| Nunpan et al. | Effect of prebiotics‐enhanced probiotics on the growth of Streptococcus mutans | |
| BR112022004527A2 (pt) | Composições com base em cepas bacterianas e seu uso como anti-inflamatórios | |
| AR035683A1 (es) | Producto de consumo que contiene probioticos | |
| Shah et al. | Determination of an antimicrobial activity of Weissella confusa, Lactobacillus fermentum, and Lactobacillus plantarum against clinical pathogenic strains of Escherichia coli and Staphylococcus aureus in co-culture | |
| Kitazawa et al. | Probiotics: immunobiotics and immunogenics | |
| Ghasempour et al. | Frequency, biofilm formation and acid susceptibility of Streptococcus mutans and Streptococcus sobrinus in saliva of preschool children with different levels of caries activity | |
| Ziar et al. | Effect of prebiotic carbohydrates on growth, bile survival and cholesterol uptake abilities of dairy‐related bacteria | |
| Miranda et al. | Development of a selective culture medium for bifidobacteria, Raffinose-Propionate Lithium Mupirocin (RP-MUP) and assessment of its usage with Petrifilm™ Aerobic Count plates | |
| Dong et al. | Lactiplantibacillus plantarum subsp. plantarum and fructooligosaccharides combination inhibits the growth, adhesion, invasion, and virulence of Listeria monocytogenes | |
| Mendi et al. | Antioxidant lactobacilli could protect gingival fibroblasts against hydrogen peroxide: a preliminary in vitro study | |
| Balan et al. | Community dynamics of subgingival microbiome in periodontitis and targets for microbiome modulation therapy | |
| Dahiya et al. | Evaluation of survival, free radical scavenging and human enterocyte adherence potential of lactobacilli with anti‐obesity and anti‐inflammatory CLA isomer‐producing attributes | |
| Sornsenee et al. | Antibacterial, antioxidant, and anti-inflammatory activities of Lacticaseibacillus paracasei lysates isolated from fermented palm sap |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |